Addex Therapeutics

Economic moat is weak. Intangibles exist via patents and know‑how in allosteric modulation, plus program‑specific IP and the Sinntaxis option for dipraglurant in brain injury recovery, but these are early and unproven clinically. There are no switching costs, network effects, or scale advantages typical of durable moats.

The Janssen termination of ADX71149 and subsequent return of rights underscores fragility rather than defensibility. Any future pricing power would be contingent on regulatory success in complex CNS indications.

We also note dependence on external partners (Indivior, Neurosterix) where Addex has limited control and only a minority economic interest, further diluting moat quality.

If a drug were approved in focused indications such as substance‑use disorders or chronic cough subpopulations, pricing leverage could be meaningful. However, Addex has no approved products, no recurring revenue, and its leading external asset (Indivior’s GABAB PAM) is controlled by the partner.

Dipraglurant’s repositioning targets post‑stroke or TBI recovery, an area with unmet need but uncertain payer dynamics and endpoints. With today’s portfolio maturity, observed pricing power is effectively zero and remains purely hypothetical pending clinical success.

Revenue is near zero and non‑recurring. Cash flows are negative and hinge on financing windows. Clinical milestones are binary and partner‑dependent, particularly the Neurosterix NTX‑253 Phase 1 completion and Indivior’s forward steps. The return of ADX71149 to Addex and re‑evaluation of its path add uncertainty.

Geographic and listing structures are straightforward (Switzerland and US), but regulatory, trial, and funding risks dominate. This profile is the opposite of the steady, toll‑like economics we seek.

Cash was CHF 0.94 million at March 31, 2026. Q1 2026 net loss was CHF 1.71 million. 2025 operating cash outflow was CHF 2.17 million. Auditors and management highlight substantial doubt about going concern. While debt is minimal, equity financing at this stage is likely dilutive.

The 20% stake in Neurosterix is non‑liquid and was marked down by share of loss in Q1 2026, limiting near‑term funding options.

Management executed a 2024 platform spin‑out into Neurosterix in exchange for cash and a 20% equity interest, cutting burn and preserving upside. They also secured the Sinntaxis option to support dipraglurant’s repositioning and maintained the Indivior partnership that progressed to IND‑enabling.

These steps show creativity, but outcomes remain unproven and cash is critically low. The company relies on selling treasury shares and ATM capacity for liquidity, which risks shareholder dilution. Net, the strategic logic is understandable, but execution is constrained by capital scarcity.

CEO Tim Dyer has long experience with Addex and meaningful shareholdings, and the team has navigated complex transactions. Still, the score reflects mixed operating results: a key partnered asset was terminated by Janssen, the company remains pre‑revenue, and financing remains precarious. Governance and disclosure quality in filings is adequate.

To earn a higher score, we would need to see durable funding, disciplined dilution control, and tangible clinical progress translating into predictable value creation.